Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Enliven Therapeutics (ELVN) Shares Outstanding (2019 - 2026)

Enliven Therapeutics has reported Shares Outstanding over the past 8 years, most recently at $60.9 million for Q1 2026.

  • Quarterly results put Shares Outstanding at $60.9 million for Q1 2026, up 24.17% from a year ago — trailing twelve months through Mar 2026 was $60.9 million (up 24.17% YoY), and the annual figure for FY2025 was $59.4 million, up 21.46%.
  • Shares Outstanding reached $60.9 million in Q1 2026 per ELVN's latest filing, up from $59.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $61.7 million in Q1 2022 and bottomed at $41.1 million in Q1 2023.
  • Median Shares Outstanding over the past 5 years was $49.0 million (2025), compared with a mean of $52.3 million.
  • The largest annual shift saw Shares Outstanding crashed 80.13% in 2022 before it soared 1056.4% in 2023.
  • Over 5 years, Shares Outstanding stood at $61.7 million in 2022, then plummeted by 33.11% to $41.3 million in 2023, then increased by 18.51% to $48.9 million in 2024, then rose by 21.46% to $59.4 million in 2025, then grew by 2.44% to $60.9 million in 2026.
  • Business Quant data shows Shares Outstanding for ELVN at $60.9 million in Q1 2026, $59.4 million in Q4 2025, and $59.3 million in Q3 2025.